(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`(19) World Intellectual Property
`Organization
`International Bureau
`
`(43) International Publication Date
`8 June 2017 (08.06.2017)
`
`WIPO!IPCT
`
`\=
`
`(10) International Publication Number
`WO 2017/093718 Al
`
`Agent: STRATAGEM IPM LIMITED; Meridian Court,
`Comberton Road, Toft, Cambridge Cambridgeshire CB23
`2RY (GB).
`
`Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
`DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
`HIN, HR, HU,ID,IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
`KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
`MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI NO, NZ,
`OM,PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
`SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, T,
`TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
`ZW.
`
`GD)
`
`International Patent Classification:
`C07D 401/12 (2006.01)
`A61K 31/433 (2006.01)
`C07D 417/04 (2006.01)
`A6LK 31/549 (2006.01)
`C07D 417/14 (2006.01)
`A6IP 35/00 (2006.01)
`C07D 487/04 (2006.01)
`A61P 25/00 (2006.01)
`C07D 513/04 (2006.01)
`
`(74)
`
`(81)
`
`(21)
`
`International Application Number:
`
`PCT/GB2016/053742
`
`(22)
`
`(25)
`
`(26)
`
`(30)
`
`(71)
`
`(72)
`
`International Filing Date:
`29 November 2016 (29.11.2016)
`
`Filing Language:
`
`Publication Language:
`
`Priority Data:
`1521109.7.
`30 November 2015 (30.11.2015)
`
`English
`
`English
`
`GB
`
`Applicant: MISSION THERAPEUTICS LIMITED
`[GB/GB]; Babraham Research Campus, Moneta (Building
`280), Cambridge Cambridgeshire CB22 3AT (GB).
`
`Inventors: KEMP, Mark Ian; c/o Mission Therapeutics
`Limited, Babraham Research Campus, Moneta (Building
`280), Cambridge Cambridgeshire CB22
`3AT (GB).
`STOCKLEY, Martin Lee; c/o Mission Therapeutics Lim-
`ited, Babraham Research Campus, Moneta (Building 280),
`Cambridge Cambridgeshire CB22 3AT (GB). MADIN,
`Andrew; c/o Mission Therapeutics Limited, Babraham Re-
`search Campus, Moneta (Building 280), Cambridge Cam-
`bridgeshire CB22 3AT (GB).
`
`(84)
`
`Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
`TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
`TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
`DK,EE, ES, FI, FR, GB, GR, HR, HU,IE, IS, IT, LT, LU,
`LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
`SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
`GW, KM, ML, MR,NE, SN, TD, TG).
`Published:
`
`with international search report (Art. 21(3))
`
`(54) Title: 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30.
`
`
`
`(I)
`
`
`
`2017/093718AXIMIRNATATIATTATA0TITEL
`
`(57) Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatin-
`genzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific
`Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochon-
`© drial dysfunction and cancer. Compounds of the invention include compounds having the formula (1) (1) or a pharmaceutically ac -
`WwW ceptable salt thereof, wherein R', R’, R*, m, L and X are as defined herein.
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30.
`
`The present invention relates to novel compounds and methods for the manufacture of inhibitors of
`
`deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-
`
`terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to
`
`the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in
`
`the treatment of cancer.
`
`
`Background to the Invention
`
`10
`
`15
`
`20
`
`25
`
`30
`
`The listing or discussion of an apparently prior-published document in this specification should not
`
`necessarily be taken as an acknowledgement that the document is part of the state of the art or is
`
`common general knowledge.
`
`Ubiquitin is a small protein consisting of 76 amino acidsthat 1s important for the regulation of protein
`
`function in the cell. Ubiquitylation and deubiquitylation are enzymatically mediated processes by
`
`which ubiquitin is covalently bound or cleaved from a target protein by deubiquitylating enzymes
`
`(DUBs), of which there are approximately 95 DUBs in humancells, divided into sub-families based
`
`on sequence homology. The USP family are characterised by thcir common Cys and His boxcs which
`
`contain Cys and His residues critical for their DUB activities. The ubiquitylation and deubiquitylation
`
`processes have been implicated in the regulation of many cellular functions including cell cycle
`
`progression, apoptosis, modification of cell surface receptors, regulation of DNA transcription and
`
`DNA repair. Thus, the ubiquitin system has been implicated in the pathogenesis of numerous disease
`
`states including inflammation, viral infection, metabolic dysfunction, CNS disorders, and oncogenesis
`
`(Clague et al., Physiol Rev 93:1289-1315, 2013).
`
`Ubiquitin is a master regulator of mitochondrial dynamics. Mitochondria are dynamic organelles
`
`whose biogenesis, fusion and fission events are regulated by the post-translational regulation via
`
`ubiquitylation of many key factors such as mitofusins. While ubiquitin ligases such as parkin are
`
`known to ubiquitylate a number of mitochondrial proteins, until recently, deubiquitylating enzymes
`
`remained elusive. USP30 is a 517 amino acid protein which is found in the mitochondrial outer
`
`membrane (Nakamura ct al., Mol Biol 19:1903-11, 2008).
`
`It is the sole dcubiquitylating cnzyme
`
`bearing a mitochondrial addressing signal and has been shown to deubiquitylate a number of
`
`mitochondrial proteins.
`
`It has been demonstrated that USP30 opposes parkin-mediated mitophagy
`
`and that reduction of USP30 activity can rescue parkin-mediated defects in mitophagy (Bingolet al.,
`
`35
`
`Nature 510:370-5, 2014).
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`Mitochondrial dysfunction can be defined as diminished mitochondrial content (mitophagy or
`
`mitochondrial biogenesis), as a dccrcasc in mitochondrial activity and oxidative phosphorylation, but
`
`also as modulation of reactive oxygen species (ROS) generation. Hence a role for mitochondrial
`
`dysfunctions in a very large number of aging processes and pathologies including but not limited to,
`
`neurodegenerative diseases (c.g. Parkinson’s disease (PD), Alzheimer’s disease, Huntington’s disease,
`
`Amylotrophic Lateral Sclerosis (ALS), multiple sclerosis), cancer, diabetes, metabolic disorders,
`
`cardio-vascular diseases, psychiatric diseases (e.g. Schizophrenia), and osteoarthnitis.
`
`For example, Parkinson’s disease affects around 10 million people worldwide (Parkinson’s Disease
`
`Foundation) and is characterised by the loss of dopaminergic neurons in the substantia nigra. The
`
`exact mechanisms underlying PD are unclear; however mitochondrial dysfunction is increasingly
`
`appreciated as a key determinant of dopaminergic neuronal susceptibility in PD and is a feature of
`
`both familial and sporadic disease, as well as in toxin-induced Parkinsonism. Parkin is one of a
`
`numberof proteins that have been implicated with carly onset PD. While most PD cases are linked to
`
`defects in alpha-synuclein, 10% of Parkinson’s cases are linked to specific genetic defects, one of
`
`which is in the ubiquitin E3 ligase parkin. Parkin and the protein kinase PTEN-induced putative
`
`kinase
`
`1
`
`(PINK1) collaborate to ubiquitylate mitochondrial membrane proteins of damaged
`
`mitochondria resulting in mitophagy. Dysregulation of mitophagy results in increased oxidative
`
`stress, which has been described as a characteristic of PD.
`
`Inhibition of USP30 could therefore be a
`
`potential strategy for the treatment of PD. For example, PD patients with parkin mutations leading to
`
`reduced activity could be therapeutically compensated by inhibition of USP30.
`
`It has been reported that depletion of USP30 enhances mitophagic clearance of mitochondna and also
`
`enhances
`
`parkin-induced
`
`cell
`
`death
`
`(Liang
`
`et
`
`al.
`

`
`EMBO)
`
`Reports
`
`2015
`
`DOL:
`
`10.15252/embr.201439820). USP30 has also been shown to regulate BAX/BAK-dependent apoptosis
`
`independently of parkin over expression. Depletion of USP30 sensitises cancer cells to BH-3
`
`mimetics such as ABT-737, without the need for parkin over expression. Thus, an anti-apoptotic role
`
`has been demonstrated for USP30 and USP30 is therefore a potential target for anti-cancer therapy.
`
`The ubiquitin-proteasome system has gained interest as a target for the treatment of cancer following
`
`the approval of the proteasome inhibitor bortezomib (Velcade®) for the treatment of multiple
`
`myeloma. Extended treatment with bortezomib is
`
`limited by its associated toxicity and drug
`
`resistance. However, therapeutic strategies that target specific aspects of the ubiquitin-proteasome
`
`pathway upstrcam of the protcascomc, such as DUBs, are predicted to be better tolcrated (Bedford ct
`
`al., Nature Rev 10:29-46, 2011). Thus,
`
`there is a need for compounds and pharmaceutical
`
`compositions to inhibit DUBs such as USP30 for the treatment of indications where DUBactivity is
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`observed,
`cancer.
`
`including, although not limited to, conditions involving mitochondrial dysfunction and
`
`Summary of the Invention
`
`In accordance with a first aspect of the invention there is provided a compound of formula (1)
`
`a
`
`or a pharmaceutically acceptable salt thereof, wherem:
`
`10
`
`15
`
`m is an integer from 0 to 3;
`each occurrence of R'
`is independently selected from the group consisting of fluorine, cyano,
`
`hydroxyl, amino, optionally substituted C)-C. alkyl, optionally substituted C\-C, alkoxy or an
`
`optionally substituted 3 to 6 membered ring;
`R’ represents hydrogen, optionally substituted C)-Cs alkyl, an optionally substituted ring, or R’
`together with R* formsan optionally further substituted ring:
`R° represents hydrogen, optionally substituted C)-C. alkyl, an optionally substituted ring, or R°
`together with R* forms an optionally further substituted ring, or R* together with X forms an
`
`optionally substituted ring;
`
`L represents a bond, an optionally substituted C,-C, alkylene or optionally substituted -C-C,
`alkenylene linker or formspart of a ring with X and R’;
`
`20
`
`X represents hydrogen, optionally substituted C,-C, alkyl, an optionally substituted ring, or X together
`with R* forms an optionally substituted ring.
`
`In one aspect, the invention also relates to pharmaceutical compositions comprising the compounds of
`
`the present invention and one or more pharmaceutically acceptable excipients.
`
`In another aspect, the compoundsof the invention are useful for the treatment of cancer or a disease or
`
`condition involving mitochondrial dysfunction.
`
`25
`
`30
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`
`Brief Description of the Figures
`
`Figure 1 is a graph showing protcolytic activity of USP30 measured using a fluorescence polarisation
`
`assay. Various volumes of purified USP30 as indicated were incubated with a TAMRA labelled
`
`peptide linked to ubiquitin via an isopeptide bond.
`
`
`Detailed Description of the Invention
`
`The definitions and explanations below are for the terms as used throughout this entire document
`
`including both the specification and the claims. Reference to compoundsas described herein (e.g. a
`
`compound of formula (1),
`
`includes reference to formula (I) and formula (II) including any sub-
`
`generic embodiments thereof, e.g. formula (IA), (IB) or (IC) (including all sub-generic embodiments
`
`thereof).
`
`Where any group of the compounds of formula (I) or (ID) have been referred to as optionally
`
`substituted, this group may be substituted or unsubstituted. Substitution may be by one or more of the
`
`specified substituents which may be the sameor different.
`
`It will be appreciated that the number and
`
`nature of substituents will be selected to avoid any sterically undesirable combinations.
`
`In the context of the present specification, unless otherwise stated an alkyl, alkylene, alkoxy, alkenyl,
`
`alkenylene or alkynyl substituent (or linker) group or an alkyl, alkenyl moiety in a substituent group
`
`may be linear or branched. Alkyl, alkylene, alkenyl and alkenylene chains may also include
`
`intervening heteroatoms such as oxygen,
`
`C,-C, alkyl refers to a saturated aliphatic hydrocarbon group having x-y carbon atoms which may be
`
`linear or branched. For example C,.C. alkyl contains from | to 6 carbon atoms and includes C,, C2,
`
`C3, Cu, Cs and Cs. “Branched” means that at least one carbon branch point is present in the group.
`
`For example, tert-butyl and isopropyl are both branched groups. Examples of C,-C, alkyl groups
`
`include methyl, ethyl, propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-
`
`butyl, 2-methyl-3-butyl, 2,2-dimethyl-l-propyl, 2-methyl-pentyl, 3-methyl-l-pentyl, 4-methyl-1-
`
`pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-
`
`1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl and n-hexyl. C)-
`Cy alkyl, C\-C, alkyl and C.-C; alkyl within the definitions of R', R’, R’, R’, R”, R’”, R® R®, R® RY
`R°, RB‘, R&R" and R’‘, Q', Q’, Q*, X, and within the definition of substituents for R*, R° and R°, may be
`
`unsubstituted or substituted with one or more of the substituents defined herein.
`
`Examples of
`
`substituted C\-C¢ alkyl therefore include CF3, CH2CF3, CH2CN, CH2OH and CH2CH2OH.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`A C,-C, alkylene group or moiety may be linear or branched and refers to a divalent hydrocarbon
`
`group having onc Icss hydrogen atom from C,.C, alkyl as defined above. C,-Cs alkylene may include
`
`intervening heteroatoms such as oxygen, and therefore includes alkyleneoxy groups. Alkyleneoxyas
`
`employed herem also extends to embodiments in which the or an oxygen atom (c.g. a single oxygen
`
`atom) is located within the alkylene chain, for example CH2CH2,OCH2 or CH2OCH2. Examples of C,.
`
`C.e alkylene groups include methylene, methyleneoxy, ethylene, ethyleneoxy, n-propylene, n-
`
`propyleneoxy, n-butylene, n-butyleneoxy, methylmethylene and dimethylmethylene. Unless stated
`
`otherwise, Ci-C, alkylene, Ci-C, alkylene and C\-C; alkylene within the definitions of R’, R”, R”,
`R* R°, RS R° R° RY R%, R" and R', Q', Q’, Q’, L, and within the definition of substituents for R“, R°
`and R°, may be unsubstituted or substituted with one or more ofthe substituents defined herein.
`
`C.-C, alkenyl refers to a linear or branched hydrocarbon chain radical containing at least two carbon
`
`atoms and at least one double bond. Examples of alkenyl groups include ethenyl, propenyl, 2-
`
`propenyl, 1-butenyl, 2-butenyl, 1-hexenyl, 2-methyl-1-propenyl, 1,2-butadienyl, 1,3-pentadienyl, 1,4-
`pentadienyl and 1-hexadienyl. Unless stated otherwise, Co-C, alkenyl within the definitions of Q', Q’,
`Q*, and within the definition of substituents for R*, R° and R°, may be unsubstituted or substituted
`with one or more of the substituents defined herein.
`
`C.-C, alkenylene refers to linear or branched hydrocarbon group having one less hydrogen atom
`
`from C,-C, alkenyl as defined above. Examples of C.-C, alkenylene include ethenylene, propenylene
`
`and butenylene. Unless stated otherwise, C.-C, alkenylene and C2-C, alkenylene within the definition
`of substituents for Q’, Q’, Q*, Q*, Q’, Q° and L, may be unsubstituted or substituted with one or more
`
`of the substituents defined herein.
`
`C.-C, alkynyl refers to a linear or branched hydrocarbon chain radical containing at least two carbon
`
`atoms and at least one triple bond. Examples of alkenyl groups include ethynyl, propynyl, 2-
`
`propynyl, 1-butynyl, 2-butynyl and I-hexynyl. Unless specified otherwise, C2-C, alkynyl within the
`definitions of Q', Q’, Q*, and within the definition of substituents for R“, R° and R°, may be
`
`unsubstituted or substituted with one or more of the substituents defined herein.
`
`C,-C, alkoxy refers to a group or part of a group having an -O-C,.C, alkyl group according to the
`
`definition of C,.C, alkyl above. C)-C, alkoxy contains from 1 to 6 carbon atoms and includes C), Co,
`
`Cs, C4, Cs and Cs. Examples of C,-C, alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy,
`
`pentoxy and hexoxy. Alkoxy as cmployed hcrcin also cxtends to cmbodiments in which the or an
`
`oxygen atom (e.g. a single oxygen atom) is located within the alkyl chain, for example CH,CH,0CH;
`
`or CH,OCH;. Thus the alkoxy may be linked through carbon to the remainder of the molecule, for
`
`5
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`example, -CH,»CH2,OCHs, or alternatively, the alkoxy is linked through oxygen to the remainderof the
`
`molecule, for cxample -OC,« alkyl.
`
`In onc instance, the alkoxy is linked through oxygen to the
`
`remainder of the molecule but the alkoxy group contains a further oxygen atom, for example —
`
`OCH:;CH2OCH:;. Unless specified otherwise, C)-C, alkoxy and C,-C; alkoxy within the definitions
`R', R’,R’, RR”, R’”, Q', Q”, Q’ and X may be unsubstituted or substituted with one or more of the
`
`substituents defined herein. Examples of substituted C,-C, alkoxy therefore include OCF;, OCHF,
`
`OCH:CF; and OCH,COCHs;. For example, OCF;, OCH2CF; and OCH,COCHs.
`
`The term “halogen” or “halo” refers to chlorine, bromine, fluorine or iodine atoms,
`
`in particular
`
`10
`
`chlorine or fluorine atoms.
`
`The term “oxo” means =O.
`
`The term “amino” means —NH)>.
`
`15
`
`20
`
`25
`
`30
`
`35
`
`For the avoidance of doubtit will be understood that the cycloalkyl, heterocyclyl, aryl and heteroaryl
`rings disclosed herein and withinthe definitions of R', R’, R*, R*, R°, R®, R*, R®, RY, R& RY, RY RY, R"
`and R', X, ring A, ring B, ring C, and within the definition of substituents for R*, R° and R°, do not
`
`include any unstable ring structures or, in the case of heteroaryl and heterocyclic ring systems, any O-
`
`O, O-S or S-S bonds. The ring systems may be monocyclic, bicyclic or tricyclic. Bicyclic and
`
`tricyclic ring systems include bridged, fused and spiro ring systems. A substituent if present may be
`
`attached to any suitable ring atom which may be a carbon atom or, in the case of heteroaryl and
`
`heterocyclic ring systems, a heteroatom. Substitution on a ring may also include a changein the nng
`
`atomat the position of the substitution. For example, substitution on a phenyl ring may include a
`
`change in the ring atom at the position of substitution from carbon to nitrogen, resulting in a pyridine
`
`ring.
`
`“cycloalkyl” refers to a monocyclic saturated or partially unsaturated, non-aromatic ring, wherein all
`
`of the ring atoms are carbon, and having the number of ring atoms as indicated. For example C3-Cio
`
`cycloalkyl refers to a monocyclic or bicyclic hydrocarbon ring containing 3 to 10 carbon atoms.
`
`Examples of C3-Cy cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
`
`cyclooctyl and decahydronaphthalenyl. Bicyclic cycloalkyl groupsinclude bridged ring systems such
`
`as bicycloheptane and bicyclooctane. Unless specified otherwise, cycloalkyl within the definitions of
`R', R?, B®, R*, R’, R®, R® R®, RY, RY RY, RY, R&R" and RX, ring C, and within the definition of
`substituents for R*, R° and R°, may be unsubstituted or substituted with one or more of the
`
`substituents defined herein.
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`An “aryl” group / moicty refcrs to any monocyclic or bicyclic hydrocarbon group compnising at Icast
`
`one aromatic group and having from 5 to 10 carbon atom ring members. Examples of aryl groups
`
`imclude phenyl and naphthyl. Bicyclic nngs may be fused aromatic rings where both rings are
`
`aromatic, for example, naphthalenyl. Preferred aryl groups are phenyl and naphthyl, more preferably
`phenyl. Unless specified otherwise, aryl within the definitions of R', R’, R’, R*, R°, R°®, R*, R°, R®, R%,
`R®, R4, R&, R" and R’', X, ring C, and within the definition of substituents for R*, R° and R°, may be
`
`unsubstituted or substituted with one or more of the substituents defined herein.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`“Heteroaryl” as used herein means a polyunsaturated, monocyclic, bicyclic or tricyclic 5 to 14
`
`membered, or 4 to 10 membered, or 5 to 10 membered, aromatic moiety containing at least one and
`
`up to 5 heteroatoms,particular 1, 2 or 3 heteroatoms selected from N, O andS, and the remaining ring
`
`atoms are carbon atoms, in stable combinations known to the skilled person. Heteroaryl ring nitrogen
`
`and sulphur atoms are optionally oxidised, and the nitrogen atom(s) are optionally quaternized. A
`
`heteroaryl ring can be a single aromatic ring or a fused bicyclic mng where the bicyclic ring system
`
`can be aromatic, or one of the fused rings is aromatic andthe otheris at least partially saturated.
`
`In
`
`such instances, attachment of the bicyclic ring to the group it is a substituent of, e.g. with respect to
`
`the cyanopyrrolidine core,
`
`is via the aromatic ring of the bicycle.
`
`In one example, a bicyclic
`
`heteroaryl is one in whichthe entire fused ring system is aromatic. A bicyclic heteroaryl can have the
`
`at least one heteroatom in either of the fused rings, ie.
`
`it can be attached to the group it is a
`
`substituent of either via a heteroatom containing ring or a carbon only containing nng. The point of
`
`attachment of heteroaryl to the group it is a substituent of can be via a carbon atom or a heteroatom
`
`(e.g. nitrogen).
`
`In instances where nng B of formula (IB) is a heteroaryl, the ring incorporating the
`
`sulphamide nitrogen is an aromatic ring which may be fused to a further aromatic or partially
`
`saturated ring.
`
`In instances where ring C of formula (IC)is a heteroaryl, the ring is an aromatic ring
`
`which may be fused to a further aromatic or partially saturated ring. Examples of heteroaryl rings
`
`include pynidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl,
`
`tniazolyl,
`
`tetrazolyl,
`
`indolyl,
`
`indolizinyl,
`
`isomdolyl, purmnyl,
`
`furazanyl,
`
`imidazolyl,
`
`indazolyl,
`
`isothiazolyl,
`
`isoxazolyl,
`
`oxadiazolyl,
`
`tetrazolyl,
`
`thiadiazolyl, benzofuranyl,
`
`isobenzofurany],
`
`benzothiophenyl,
`
`isobenzothiophenyl, benzimidazolyl, benzothiazolyl, napthyridinyl, pteridinyl,
`
`pyrazinyl, quinolinyl,
`
`isoquinolinyl,
`
`cimnolinyl, phthalazinyl, quinazolinyl,
`
`imidazopyndinyl,
`
`triazinyl, dihydrophyridinyl, quinoxalinyl and carbazolyl.
`thiazolopyridinyl,
`pyrazolopynidinyl,
`Unless specified otherwise, heteroaryl within the definitions of R', R’?, R*, R*, R°, R®, R* R°, R®, RY
`R°, R*, R&R" and R', X, ring B, ring C, and within the definition of substitucnts for R*, R° and R°,
`
`maybe unsubstituted or substituted with one or more of the substituents defined herein.
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`“Heterocyclyl” or “heterocyclic” as used herein in describing a ring means, unless otherwise stated, a
`
`monocyclic saturated or partially unsaturatcd, non-aromatic nng, a bicyclic saturated or partially
`
`unsaturated ring, wherein the bicyclic ring system is non-aromatic, or a tricyclic partially unsaturated
`
`ring, the mono-, bi- or tricyclic ring having, for example, 3 to 14 members, or 3 to 10 members, or 4
`
`to 10 members, whereat least one member and up to 5 members, particularly 1, 2 or 3 members ofthe
`
`ring, are heteroatoms selected from N, O and S, and the remaining ring atoms are carbon atoms, in
`
`stable combinations known to those of skill in the art. Heterocyclic ring nitrogen and sulphur atoms
`
`are optionally oxidised, and the nitrogen atoms(s) are optionally quaternized. As used herein, the
`
`heterocyclic ring may be a fused ring to another ring system to form a bicycle, i.e. one or two of the
`
`heterocyclic ring carbons is commonto an additional ring system. In instances where the heterocyclyl
`
`is a bicyclic ring, attachment to the group it is a substituent of relative to the cyanopyrrolidine core is
`
`via the non-aromatic ring, wherein the non-aromatic ring may be fused to a further ring which may be
`aromatic or non-aromatic. For example, R’ and R* may together form a heterocylic ring which
`
`incorporates the sulphamide nitrogens and sulphur, and whichis also referred to as ring A in formula
`
`(IA).
`
`In the case where the heterocylcyl is a bicyclic ring, the second ring (i.e. the nng portion that
`
`does not include -N-S(O2)-N-) can be aromatic, e.g. a fused phenyl, pyridyl, pyrazolyl, or the like. In
`
`the case of a tricyclic heterocyclic ring, the heterocyclic ring may formthe central ring and be fused to
`
`two further ring systems which are preferably aromatic. The heterocyclyl may be linked through
`
`carbon or a heteroatom to the remainder of the molecule and the link may be via the central
`
`heterocyclyl or either of the fused terminal rings. Examples of heterocyclyl groups include azetidinyl,
`
`pytrolidinyl, piperidinyl,
`
`azepanyl, diazepanyl, dihydrofuranyl
`
`(e.g. 2,3-dihydrofuranyl, 2,5-
`
`dihydrofuranyl),
`
`dioxolanyl, morpholinyl,
`
`oxazolidinyl,
`
`oxazinanyl,
`
`indolinyl,
`
`isoimdolinyl,
`
`piperazinyl,
`
`tetrahydrofuranyl,
`
`thiomorpholinyl, dihydropyranyl
`
`(e.g. 3,4-dihydropyranyl, 3,6-
`
`dihydropyranyl), homopiperazinyl, dioxanyl, hexahydropynmidinyl, pyrazolinyl, pyrazolidinyl, 4H-
`
`10
`
`15
`
`20
`
`25
`quinolizinyl, tetrahydropyridinyl,—tetrahydropynmidinyl,quinuclidinyl, tetrahydropyranyl,
`
`
`
`
`
`
`
`tetrahydrothiophenyl, thiazolidinyl, benzopyranyl, tetrahydrothiazolopyridinyl, tetrahydroquinolinyl,
`
`benzomorpholinyl, tetrahydroisoquinolinyl and carbazolyl. Unless specified otherwise, heterocyclyl
`within the definitions of R', R’, R*, R*, R*, R®, R*, R®, R®, RB“, R®, RY R® R" and R’, X,ring A, ring B,
`ring C, and within the definition of substituents for R*, R° and R®, may be unsubstituted or substituted
`
`30
`
`with one or more of the substituents defined herein.
`
`Substituted heterocyclyl rings include for
`
`example 4,5-dihydro-1H-maleimido, tetramethylenesulfoxide and hydantoiny1.
`
`“Optionally substituted” as applied to any group means that the said group may if desired be
`
`substituted with onc or morc substitucnts (c.g., 1, 2, 3 or 4 substituents) which may bc the same or
`
`35
`
`different.
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`Examples of suitable substituents for “substituted” and “optionally substituted” C,-C, alkyl (including
`
`C.-C, alkyl and C)-C; alkyl),Ci-C¢ alkoxy (including C)-C, alkoxy and C)-C; alkoxy), -C2-C, alkenyl
`and -C3-C, alkynyl, for example within the definitions of R', R’, R*, R’, R’”, R’”, R*, R®, R®, R°, RY, RB’
`R&, R" and R', Q', Q’, Q*, X, and within the definition of substituents for R*, R° and R®°, and Cy-C,
`
`alkylene (including C)-C3 alkylene) and C.-C. alkenylene, for example within the definitions of R’,
`R”, R’”, R*, R°, R°, RY R® RY Re R" and R’, Q', Q’, Q? and L, include C\-Cs alkoxy, halogen,
`
`hydroxyl, thiol, cyano, amino, nitro and SF; (a known mimetic of nitro),
`
`in particular, halogen
`
`(preferably fluorine or chlorine), hydroxyl and cyano. For example, suitable substituents include
`
`halogen, hydroxyl, thiol, cyano, amino, nitro and SFs, in particular, halogen (preferably fluorine or
`
`10
`
`chlorine), hydroxyl and cyano.
`
`Examples of suitable substituents for “substituted” and “optionally substituted” rings, 1.¢. cycloalkyl,
`heterocyclyl, aryl and heteroaryl rings, for example within the definitions of R', R’, R’, R*, R’, R°, R*,
`R®, R& RY R®, RR’, R&, R"and R‘, X, ring A, ring B,ring C, and within the definition of substituents for
`R*, R° and R°, include halogen, C)-C, alkyl or C\-C; alkyl, hydroxy, C)-Cs alkoxy or C)-C; alkoxy,
`
`cyano, amino, nitro or SF;
`
`(a known mimetic of nitro), aryl, heteroaryl, heterocyclyl, C3-C¢
`
`cycloalkyl, Ci; alkylamino, C2. alkenylamino, di-C)-C; alkylamimo, C)-C; acylamino, di-C-C;
`
`acylamino, carboxy, C)-C; alkoxycarbonyl, carboxamidyl, carbamoyl, mono-C,.3; carbamoyl, di-C,;
`
`carbamoyl or any of the above in which a hydrocarbyl moiety is itself substituted by halo.
`
`In groups
`
`containing an oxygen atom such as hydroxy and alkoxy,
`
`the oxygen atom can be replaced with
`
`sulphur to make groups such as thio (SH) and thio-alkyl (S-alkyl). Optional substituents therefore
`
`include groups such as S-methyl.
`
`In thio-alkyl groups, the sulphur atom may be further oxidised to
`
`make a sulfoxide or sulfone, and thus optional substituents therefore includes groups such as S(O)-
`
`alkyl and S(O)»-alkyl.
`
`Examples of suitable substituents for “substituted” and “optionally substituted” rings include in
`
`particular,
`
`fluorine, chlorine, oxo, cyano, C)-C; alkyl, C)-C3 alkoxy, heterocyclyl, cycloalkyl,
`
`heteroary or aryl, wherein the alkyl or alkoxyis optionally substituted with one or more (e.g. one, two
`
`or three) substituents independently selected from halogen, hydroxyl, thiol, cyano, amino, nitro and
`
`SF.
`
`In particular, suitable substituents for “substituted” and “optionally substituted” rings disclosed
`
`herein include fluorine, chlorine, oxo, cyano, C)-C; alkyl, Ci-C; alkoxy, wherein the alkyl or alkoxy is
`
`optionally substituted with one or more (e.g. one, two or three) substituents selected from halogen,
`
`hydroxyl, thiol, cyano, amino, nitro and SFs, in particular, one or more fluorine.
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`Substituted groups thus include for example Br, Cl, F, CN, Me, Et, Pr, OMe, OEt, OPr, C(CHs)s,
`
`CH(CH3)2, CF3, OCF3:3, C(O)NHCHs, cyclopropyl, phenyl, ctc.
`
`In the case of aryl groups, the
`
`substitutions may be in the form of rings from adjacent carbon atoms in the aryl ring, for example
`
`cyclic acetals such as O-CH;-O.
`
`The term "treat" or "treating" or “treatment” includes prophylaxis and means to ameliorate,
`
`alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent
`
`basis, or to prevent or slow the appearance of symptoms of the named disorder or condition. The
`
`compoundsof the invention are useful in the treatment of humans and non-humananimals.
`
`The dose of the compound is that amount effective to prevent occurrence of the symptoms of the
`
`disorder or to treat some symptoms of the disorder from which the patient suffers. By "effective
`
`amount" or "therapeutically effective amount" or "effective dose" is meant that amount sufficient
`
`to elicit the desired pharmacological or therapeutic effects, thus resulting in effective prevention or
`
`treatment of the disorder. Prevention of the disorder is manifested by delaying the onset of the
`
`symptoms of the disorder to a medically significant extent. Treatment of the disorder is manifested by
`
`a decrease in the symptoms associated with the disorder or an amelioration of the reoccurrence of the
`
`symptoms of the disorder.
`
`Pharmaceutically acceptable salts of the compounds of the invention include but are not limited to
`
`addition salts (for example phosphates, nitrates, sulphates, borates, acetates, maleates, citrates,
`
`fumarates, succinates, methanesulphonates, benzoates, salicylates and hydrohalides), salts derived
`
`from organic bases (such as lithium, potasstum and sodium), salts of amino acids (such as glycine,
`
`alanine, valine,
`
`leucine,
`
`isoleucine, cysteine, methionine and proline),
`
`inorganic bases (such as
`
`triethylamine,
`
`hydroxide,
`
`choline,
`
`thiamine
`
`and N-N’-diacetylethylenediamine).
`
`Other
`
`pharmaceutically acceptable salts
`
`include ammonium salts,
`
`substituted ammonium salts and
`
`aluminium salts. Further pharmaceutically acceptable salts include quaternary ammoniumsalts of the
`
`compoundsof the invention.
`
`General methods for the production of salts are well known to the person skilled in the art. Such salts
`
`may be formed by conventional means, for example by reaction of a free acid or a free base form of a
`
`compound with one or more equivalents of an appropriate acid or base, optionally in a solvent, or ina
`
`medium in whichthesalt is insoluble, followed by removal of said solvent, or said medium, using
`
`standard techniqucs (c.g. in vacuo, by freeze-drying or byfiltration). Salts may also be prepared by
`
`exchanging a counter-ion of a compound in the form of a salt with another counter-ion, for example
`
`using a suitable ion exchange resin.
`
`10
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/093718
`
`PCT/GB2016/053742
`
`Where compoundsof the invention cxist in differcnt cnantiomcric and/or diastcrcoisomcric forms, the
`
`invention relates to these compounds prepared as isomeric mixtures or racemates whether present in
`
`an optically pure form or as mixtures with other isomers. Enantiomers differ only m their ability to
`
`rotate plane-polarized light by equal amounts in opposite directions and are denoted as the (+) / (S) or
`
`(-) /(2) forms respectively. Individual enantiomer

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket